bortezomib ever pharma bortezomib 2.5 mg/1 ml solution for injection vial
interpharma pty ltd - bortezomib, quantity: 2.5 mg - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; sodium hydroxide; water for injections; mannitol - bortezomib ever pharma, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy. bortezomib ever pharma, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. bortezomib ever pharma is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease. bortezomib ever pharma in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.
bortezomib for injection powder for solution
pfizer canada ulc - bortezomib (bortezomib mannitol boronic ester) - powder for solution - 2.5mg - bortezomib (bortezomib mannitol boronic ester) 2.5mg - antineoplastic agents
bortezomib for injection powder for solution
pfizer canada ulc - bortezomib (bortezomib mannitol boronic ester) - powder for solution - 3.5mg - bortezomib (bortezomib mannitol boronic ester) 3.5mg - antineoplastic agents
bortezomib mylan
viatris limited - bortezomib 3.5mg (as a bortezomib mannitol boronic ester) - powder for injection - 3.5 mg - active: bortezomib 3.5mg (as a bortezomib mannitol boronic ester) excipient: mannitol nitrogen - bortezomib mylan in combination with melphalan and prednisone, is indicated for the treatment of patients with previously untreated multiple myeloma, who are not suitable for high dose chemotherapy. bortezomib mylan as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. bortezomib mylan is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.
bortezomib s.k. 3.5 mg
k.s.kim international (sk- pharma) ltd., israel - bortezomib as mannitol boronic ester - powder for solution for injection - bortezomib as mannitol boronic ester 3.5 mg - bortezomib - multiple myelomabortezomib s.k is indicated for the treatment of patients with multiple myeloma.mantle cell lymphomabortezomib s.k is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy.bortezomib s.k in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.
bortezomib for injection powder for solution
auro pharma inc - bortezomib (bortezomib mannitol boronic ester) - powder for solution - 3.5mg - bortezomib (bortezomib mannitol boronic ester) 3.5mg - antineoplastic agents
bortezomib 3.5mg powder for solution for injection
baxter holding b.v. kobaltweg 49, 3542ce utrecht, netherlands - bortezomib - powder for solution for injection - bortezomib 3.5 mg - antineoplastic agents
bortezomib for injection powder for solution
eugia pharma inc. - bortezomib (bortezomib mannitol boronic ester) - powder for solution - 3.5mg - bortezomib (bortezomib mannitol boronic ester) 3.5mg
taro-bortezomib powder for solution
taro pharmaceuticals inc - bortezomib (bortezomib mannitol boronic ester) - powder for solution - 1mg - bortezomib (bortezomib mannitol boronic ester) 1mg - antineoplastic agents
act bortezomib powder for solution
teva canada limited - bortezomib (bortezomib mannitol boronic ester) - powder for solution - 3.5mg - bortezomib (bortezomib mannitol boronic ester) 3.5mg - antineoplastic agents